Trevena's IV Opioid Not Quite 'Ready for Primetime,' US FDA Panel Concludes

Advisory committee votes 8-7 against approval of the novel opioid; several members say they would change their vote with more data.

Infusion of a hospital

While a US FDA advisory panel narrowly voted against approval of Trevena Inc.'s intravenous opioid Olinvo (oliceridine) on Oct. 11, several members indicated that the drug could get their support with more data.

The Anesthetic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval of the drug for acute pain in...

More from US FDA Performance Tracker

More from Regulatory Trackers